A regression tree approach to identifying subgroups with differential treatment effects

In the fight against hard‐to‐treat diseases such as cancer, it is often difficult to discover new treatments that benefit all subjects. For regulatory agency approval, it is more practical to identify subgroups of subjects for whom the treatment has an enhanced effect. Regression trees are natural f...

Full description

Saved in:
Bibliographic Details
Published inStatistics in medicine Vol. 34; no. 11; pp. 1818 - 1833
Main Authors Loh, Wei-Yin, He, Xu, Man, Michael
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 20.05.2015
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In the fight against hard‐to‐treat diseases such as cancer, it is often difficult to discover new treatments that benefit all subjects. For regulatory agency approval, it is more practical to identify subgroups of subjects for whom the treatment has an enhanced effect. Regression trees are natural for this task because they partition the data space. We briefly review existing regression tree algorithms. Then, we introduce three new ones that are practically free of selection bias and are applicable to data from randomized trials with two or more treatments, censored response variables, and missing values in the predictor variables. The algorithms extend the generalized unbiased interaction detection and estimation (GUIDE) approach by using three key ideas: (i) treatment as a linear predictor, (ii) chi‐squared tests to detect residual patterns and lack of fit, and (iii) proportional hazards modeling via Poisson regression. Importance scores with thresholds for identifying influential variables are obtained as by‐products. A bootstrap technique is used to construct confidence intervals for the treatment effects in each node. The methods are compared using real and simulated data. Copyright © 2015 John Wiley & Sons, Ltd.
Bibliography:ArticleID:SIM6454
ark:/67375/WNG-7TKX0R0Q-V
Eli Lilly and Company
US Army Research Office - No. W911NF-09-1-0205; No. DMS-1305725; No. P50CA143188
istex:0D62E7DC9B1ABCD38A248DF48B63B901FF5C63E0
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0277-6715
1097-0258
1097-0258
DOI:10.1002/sim.6454